Previous CD123-targeting approaches, such as Fc-enhanced IgG1-based antibodies and T cell engagers, including combinations with hypomethylating agents, showed unfavorable risk/benefit profiles in the clinic due to limited efficacy and/or challenging safety profiles, including the risk of cytokine release syndrome (CRS)13–19. The gene discussed is IL3RA; the disease is congenital rubella syndrome.